Home › Funds › Boston Partners › GILD

Boston Partners position in GILD

GILEAD SCIENCES INC · Health Care

Boston Partners reported holding 6,523,864 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$970.4M, representing 0.87% of its reported portfolio and ranking #26 among its reported holdings. Boston Partners has disclosed GILD holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)6.52M sh
Reported value held$970.37M
Portfolio Weight0.87%
First reportedQ4 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Boston Partners's GILD position evolved

Boston Partners first disclosed a stake in GILD in Q4 2025 at 4,220,501 shares (US$517.8M). The position peaked in Q3 2026 at 6,523,864 shares, worth US$970.4M. Across 4 filings, Boston Partners increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 6,523,864 shares valued at US$970.4M — an increase of 505,906 shares quarter over quarter.. Notable position changes include a 41% increase in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 4.22M $517.81M New
Q1 2026 4.26M $593.12M Add
Q2 2026 6.02M $761.61M Add
Q3 2026 6.52M $970.37M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 33 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Boston Partners held GILD?

Boston Partners has disclosed GILD holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Boston Partners's current position in GILD?

As of Q3 2026, Boston Partners holds 6.52M shares of GILD (GILEAD SCIENCES INC), valued at $970.37M, representing 0.87% of its reported portfolio and ranking #26.

Has Boston Partners been buying or selling GILD?

In the latest 13F filing (Q3 2026), Boston Partners increased its position in GILD. The position peaked in Q3 2026 at 6.52M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.